Ponatinix-15/45mg-Ponatinib | Buy Online

Package Insert of Ponatinix-15/45mg-Ponatinib

Description

Ponatinix-15/45mg-Ponatinib also known as ICLUSIG, is a tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It works by blocking the activity of several tyrosine kinases, including BCR-ABL, which causes CML and Ph+ ALL. Ponatinix-15/45mg helps stop the growth and spread of cancer cells. It is an oncology-category medicine made by Bangladeshi pharmaceutical BEACON Pharma. Ponatinix-15/45mg is highly effective and is indicated for adult patients in the chronic phase, accelerated phase, and blast phase of CML, or PH+ALL for those who cannot take other tyrosine kinase inhibitor therapy. It is also indicated for adult patients with T315l-positive CML or T315l-positive Philadelphia chromosome-positive Acute Lymphoblastic Leukemia.

Indications

Ponatinix-15/45mg-Ponatinib is a medication used to treat adult patients with Chronic phase (CP) chronic myeloid leukemia (CML) who have resistance or intolerance to at least two previous kinase inhibitors. It is also used to treat Accelerated phase (AP) or blast phase (BP) CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in patients who have resistance or intolerance to prior kinase inhibitor therapy. While Ponatinix is a very effective drug, it also has several significant side effects. Therefore, it should only be used under the supervision of an experienced doctor in the treatment of CML and Ph+ ALL.

It is important to know that Ponatinix is not a cure for CML or Ph+ ALL. However, it can help extend patient survival and improve their quality of life. Before starting Ponatinix treatment, the risks and benefits should be carefully weighed, and it should only be used under the supervision of an experienced doctor in the treatment of CML and Ph+ ALL.

Mechanism of Action

Ponatinix-15/45mg-Ponatinib is a type of medication called a tyrosine kinase inhibitor (TKI). Tyrosine kinases are enzymes that help regulate cell growth and division. Ponatinix works by stopping several different tyrosine kinases, including BCR-ABL, which is an abnormal protein that causes chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Ponatinix attaches to the active site of BCR-ABL, preventing it from binding to ATP and transferring phosphate groups to other proteins. This blocks the signaling pathway that drives the growth and survival of CML and Ph+ ALL cells.

Ponatinix is also a multi-targeted TKI, which means that it can block the activity of other tyrosine kinases as well as BCR-ABL. This makes it a very effective medication for CML and Ph+ ALL cells that have become resistant to other TKIs.

Ponatinix is a very potent medication and can be effective in treating patients who have failed other TKI therapies. However, it is important to note that ponatinib can cause serious side effects, including arterial and venous thrombotic events, myelosuppression, hepatotoxicity, pancreatitis, hypertension, skin reactions, and gastrointestinal issues.

Dosage and Administration

The recommended dose of Ponatinix is 45 mg taken orally once daily. It is important to take Ponatinix at the same time each day to maintain consistent levels in the blood. Ponatinib can be taken with or without food. However, it is important to avoid taking ponatinib with grapefruit juice, as this can increase the risk of side effects. You should swallow the tablets whole with water and avoid crushing, chewing, or dissolving them.

If you forget to take your dose of Ponatinix, take it as soon as you remember. However, if it’s almost time for your next dose, skip the missed dose and stick to your regular dosing schedule. Do not take a double dose of Ponatinix to make up for a missed one.

It’s important to note that ponatinib can cause serious side effects, including arterial and venous thrombotic events, myelosuppression, hepatotoxicity, pancreatitis, hypertension, skin reactions, and gastrointestinal side effects. Therefore, you should only use Ponatinix under the supervision of a doctor who is experienced in treating CML and Ph+ ALL. Before starting ponatinib, the doctor should carefully weigh the risks and benefits of treatment.

Important information:

• Ponatinix is a prescription medication and should only be taken under the supervision of a doctor.
• Ponatinix is not a cure for CML or Ph+ ALL. However, it can help to extend survival and improve quality of life for patients with these diseases.
• Ponatinib can cause a number of serious side effects. The risks and benefits of treatment should be carefully weighed before starting Ponatinix.

 Side Effects of Ponatinix-15/45mg-Ponatinib

Ponatinix is a very effective drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, it is also a very potent drug, and it can cause a number of serious side effects, including:

• Arterial and venous thrombotic events, such as heart attack, stroke, and blood clots
• Myelosuppression, which is a decrease in the production of blood cells
• Hepatotoxicity, which is damage to the liver
• Pancreatitis
• Hypertension
• Skin reactions
• Gastrointestinal side effects, such as diarrhea, nausea, and vomiting
• Muscle and bone pain

Clinical Trials and Success Rate of Ponatinix-15/45mg-Ponatinib

Ponatinix has been evaluated in a number of clinical trials for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

In one phase 2 trial, Ponatinix was shown to be highly effective in patients with CML who were resistant or intolerant to other tyrosine kinase inhibitors (TKIs). At 12 months, 89% of patients achieved a complete cytogenetic response (CCyR) and 67% achieved a major molecular response (MMR). At 24 months, the CCyR rate was 86% and the MMR rate was 78%.

In another phase 2 trial, Ponatinix was shown to be effective in patients with Ph+ ALL who were resistant or intolerant to other TKIs. At 12 months, 53% of patients achieved a complete remission (CR) and 77% achieved a major molecular remission (MMR). At 24 months, the CR rate was 50% and the MMR rate was 69%.

Ponatinix has also been evaluated in a number of other clinical trials, including trials in patients with newly diagnosed CML, patients with CML in blast phase, and patients with Ph+ ALL in blast phase. In all of these trials, Ponatinixb has been shown to be highly effective.

Cost and Access of Medication

Anti-cancer medicines are very expensive almost 90% of cancer patients can not afford these medicine. Some of them get access of these medicines by their insurance but insurance cost is also high for these medicines. That’s why patients do not get proper treatment. Meds for Cancer make these medicine affordable for those patients who cannot buy these expensive medicine or they are not covered by health insurance. We provide the best quality medicine at best price at every corner of the world. To know the Price of these medicine get in touch with us. Contacting us is very easy you can use this number +8801304498958 to contact through WhatsApp and Wechat.

See also Ponaxen -15/45 mg, Dasanix-50mg, Ibruxen-140mg, Ibruxen-140mg, Ventoxen-100mg

Here are some questions and their answers frequently asked by people on the internet-

1. How to use Ponatinix-15/45mg-Ponatinib?

Ponatinib is an oral drug that comes as a tablet. Patients have to take this drug every day at the same time. They can not take more or less dosage of ponatinib which can be harmful to them. They must follow the rules determined by the doctor and the prescription label.

2. Is Ponatinix-15/45mg-Ponatinib a chemotherapy drug?

Ponatinib is not a chemotherapy drug it is a multi-targeted tyrosine kinase inhibitor that is very effective to treat CML and Ph+ALL.

3. What does BCR-ABL mean?

If your diagnosis result shows that you have BCR-ABL as well as an abnormal amount of white blood cells probably you will be treated with CML and PH+ALl.

4. Is Ponatinix-15/45mg-Ponatinib better than dasatinib?

For the treatment of white blood cells cancer ponatinib shows more potential than dasatinib which means Ponatinib has more potential than dasatinib. Ponatinib induces apoptosis and inhibits the proliferation of CML cells in consensus with IPA and GO analysis results.

5. Is Ponatinix-15/45mg-Ponatinib apporved by FDA?

Ponatinib is initially approved by FDA under the FDA’s accelerated program because it is intended to treat rare diseases and conditions.

you may have a look for other medicine available to us.